NASDAQ:CLEUKeros Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Keros Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $4.19 -0.06 (-1.41 %) (As of 05/29/2020 04:00 PM ET) Add Compare Share Today's Range$3.62Now: $4.19▼$4.3050-Day Range N/A52-Week Range$3.55Now: $4.19▼$5.42Volume25,700 shsAverage Volume36,700 shsMarket Capitalization$26.52 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAdvanced ChartCompetitorsHeadlinesSocial Media China Liberal Education Holdings Limited provides educational services and products for schools and students under the China Liberal brand name in China. The company offers Sino-foreign jointly managed and delivered academic programs, including undergraduate and postgraduate education, as well as diploma and non-degree higher education, and senior secondary education programs in the areas of languages, liberal arts, and businesses. It also provides overseas study consulting and technological consulting services for Chinese universities to enhance their campus information and data management system, as well as to optimize their teaching, operating, and management environment. In addition, the company develops and provides textbooks and other course materials to students enrolled under the Sino-foreign Jointly Managed Academic Programs, as well as offers job readiness training to graduating students. China Liberal Education Holdings Limited was founded in 2019 and is based in Beijing, China.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Keros Therapeutics. Previous Next 0.0 Community Rank Outperform VotesKeros Therapeutics has received 0 “outperform” votes. (Add your “outperform” vote.)Underperform VotesKeros Therapeutics has received 0 “underperform” votes. (Add your “underperform” vote.)MarketBeat's community ratings are surveys of what our community members think about Keros Therapeutics and other stocks. Vote “Outperform” if you believe CLEU will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CLEU will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldKeros Therapeutics does not currently pay a dividend.Dividend GrowthKeros Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Keros Therapeutics insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.00 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry N/A Sub-IndustryN/A SectorConsumer Discretionary Current SymbolNASDAQ:CLEU Previous Symbol CUSIPN/A CIKN/A Webwww.chinaliberal.com Phone86-10-6597-8118Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees80 Outstanding Shares6,330,000Market Cap$26.52 million Next Earnings DateN/A OptionableNot Optionable NASDAQ:CLEU Rates by TradingView Receive CLEU News and Ratings via Email Sign-up to receive the latest news and ratings for CLEU and its competitors with MarketBeat's FREE daily newsletter. Keros Therapeutics (NASDAQ:CLEU) Frequently Asked Questions Has Keros Therapeutics been receiving favorable news coverage? News headlines about CLEU stock have been trending neutral this week, according to InfoTrie Sentiment. The research firm identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Keros Therapeutics earned a daily sentiment score of 0.5 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutKeros Therapeutics. Who are some of Keros Therapeutics' key competitors? Some companies that are related to Keros Therapeutics include Cumulus Media (CMLS), Genius Brands International (GNUS), Lincoln Educational Services (LINC), Townsquare Media (TSQ), Phoenix New Media (FENG), Ted Baker (TBAKF), Party City Holdco (PRTY), AeroGrow International (AERO), iHeartMedia (IHRTQ), Civeo (CVEO), Flexsteel Industries (FLXS), Culp (CULP), Reading International (RDI), Barnes & Noble Education (BNED) and RYB Education (RYB). View all competitors. Who are Keros Therapeutics' key executives? Keros Therapeutics' management team includes the following people: Mr. Jianxin Zhang, CEO & Chairman (Age 49)Mr. Wenhuai Zhuang, Chief Fin. Officer (Age 34)Shuming Miao, Operations DirectorMr. Nan Hu, Technical Director (Age 38)Geng Chen, Director of HR When did Keros Therapeutics IPO? (CLEU) raised $8 million in an initial public offering (IPO) on Friday, May 8th 2020. The company issued 1,300,000 shares at a price of $6.00 per share. Boustead Securities served as the underwriter for the IPO. What is Keros Therapeutics' stock symbol? Keros Therapeutics trades on the NASDAQ under the ticker symbol "CLEU." When does Keros Therapeutics' quiet period expire? Keros Therapeutics' quiet period expires on Wednesday, June 17th. Keros Therapeutics had issued 1,333,333 shares in its public offering on May 8th. The total size of the offering was $7,999,998 based on an initial share price of $6.00. During Keros Therapeutics' quiet period, insiders and any underwriters that worked on the IPO are prevented from issuing any earnings forecasts or research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the expiration of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company. How do I buy shares of Keros Therapeutics? Shares of CLEU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Keros Therapeutics' stock price today? One share of CLEU stock can currently be purchased for approximately $4.19. How big of a company is Keros Therapeutics? Keros Therapeutics has a market capitalization of $26.52 million. Keros Therapeutics employs 80 workers across the globe. What is Keros Therapeutics' official website? The official website for Keros Therapeutics is www.chinaliberal.com. How can I contact Keros Therapeutics? Keros Therapeutics' mailing address is HUATENG CENTURY PARK HEADQUARTERS BUILDING A LEVEL 2, BEIJING F4, . The company can be reached via phone at 86-10-6597-8118. This page was last updated on 5/30/2020 by MarketBeat.com Staff
